share_log

Baird Maintains Outperform on EyePoint Pharmaceuticals, Lowers Price Target to $38

Benzinga ·  May 8 07:02

Baird maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Outperform and lowers the price target from $46 to $38.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment